Lv4
510 积分 2020-12-25 加入
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
1个月前
已关闭
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
1个月前
已关闭
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
1个月前
已关闭
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
1个月前
已关闭
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
1个月前
已完结
Urinary metabolomics analysis of patients with renal tubular dysfunction after PCI surgery
1个月前
已完结
β-Catenin mediated TAM phenotype promotes pancreatic cancer metastasis via the OSM/STAT3/LOXL2 axis
4个月前
已完结
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
4个月前
已完结
Cancer drugs and acute kidney injury: new therapies and new challenges
4个月前
已完结
Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy
4个月前
已关闭
皖公网安备34019202002308
